Marco Meglio

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.

Compared to participants with ≤1 healthy lifestyle factor, the risk of developing Alzheimer disease was 37% lower in those with 2 or 3, and 60% lower in those with 4 or 5 healthy lifestyle factors.

Preliminary results showed that SRP-9001 is associated with clinically meaningful improvement that is greater than that observed with standard-of-care treatment, including corticosteroids.

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.

Emphasis on prevention of intracranial hemorrhage at an early stage is recommended to mitigate further risks later in a patient’s life, especially in older individuals.

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Effectively addressing vascular risk factors could provide an important avenue for modifying white matter hyperintensity disease burden.

An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.

The study confirmed previous study findings that indicated potential severe conditions such as stroke or inflammatory diseases can appear in later stages of COVID-19, including during recovery.

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

Coutinho et al. noted that future studies that feature a larger population will help to better determine recovery rates after endovascular treatment.

Approximately one-fourth of the excess cases of maternal stroke associated with migraine were attributable to hypertensive disorders.

The first study to attempt to directly compare 3 debated treatment strategies to treat medication overuse headache showed the most significant change in monthly headache days by using withdrawal plus preventive treatment.

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

Non-work-related activity impairment was statistically significantly reduced in the galcanezumab group compared to placebo.

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.

Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.

Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.

A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.